Citigroup Downgrades Hims & Hers Health (NYSE:HIMS) to Neutr

Citigroup downgraded shares of Hims & Hers Health (NYSE:HIMS – Free Report) from a buy rating to a neutral rating in a report published on Wednesday, MarketBeat.com reports. Citigroup currently has $20.00 price target on the stock, up from their previous price target of $16.00. Several other equities analysts have also issued reports on HIMS. […]

Related Keywords

United Kingdom , United States , Leerink Partnrs , Irene Becklund , Melissa Baird , Piper Sandler , Analyst Recommendations For Hims Hers Health , Investment Advisers , Hims Hers Health , Hims Hers Health Company Profile , Corton Capital Inc , Hims Hers Health Stock , Institutional Trading Of Hims Hers Health , Belpointe Asset Management , Hims Hers Health Inc , Securities Exchange Commission , News Ratings For Hims Hers Health Daily , Citigroup , Canaccord Genuity Group , Hers Health , Free Report , Moderate Buy , Get Free Report , Exchange Commission , Asset Management , Corton Capital , Hers Health Daily ,